Please ensure Javascript is enabled for purposes of website accessibility

Why MacroGenics Stock Is Tanking Today

By Keith Speights – Sep 16, 2021 at 12:18PM

Key Points

  • MacroGenics reported results from part of a phase 3 study of a margetuximab-retifanlimab combo.
  • It also announced preliminary data from a phase 1 study of experimental cancer drug MGC1018.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors weren't thrilled with the company's latest clinical data.

What happened

Shares of MacroGenics (MGNX -0.29%) were tanking 26.4% lower as of 11:39 a.m. EDT on Thursday. The big decline came after the company announced data from a cohort in a phase 3 study evaluating margetuximab in combination with retifanlimab in treating gastroesophageal adenocarcinoma, cancer of the stomach and esophageal junction with the stomach. MacroGenics also announced preliminary data from a phase 1 clinical study evaluating MGC018 in treating advanced solid tumors.

So what

MacroGenics reported that 21 of 40 patients in the phase 3 cohort who received the margetuximab-retifanlimab combo achieved confirmed responses with tumor shrinkage observed at the first scan of 78% of patients. The company said that the median duration of response was 10.3 months. It also noted that the combo was tolerated relatively well with no life-threatening adverse events, although 19% of patients experienced severe adverse events.

A scientist looking through a microscope.

Image source: Getty Images.

The company also said that 21 of 39 patients in the prostate cancer expansion cohort of the phase 1 study of MGC018 achieved at least 50% prostate-specific antigen (PSA) reduction. Of the 16 patients evaluable for tumor response, 10 experienced some anti-tumor activity. Four of those patients had partial responses (tumor size reduction) -- two of which were confirmed and two were unconfirmed.

In the non-small cell lung cancer (NSCLC) cohort of the phase 1 study, 13 of 16 evaluable patients experienced some level of anti-tumor activity. Four of those patients achieved partial responses that were unconfirmed.

The company stated that 7% of patients discontinued the MCG018 study due to treatment-related adverse events. MacroGenecis reported that most of the adverse events have been "clinically manageable" so far. However, there were two fatalities -- one due to COVID-19 and another from an unidentified cause.

MacroGenics CEO Scott Koenig was upbeat about the data from both studies. However, investors clearly weren't so happy.

Now what

MacroGenics now plans to discuss the late-stage results for the margetuximab-retifanlimab combo with the U.S. Food and Drug Administration. The company is also enrolling patients in additional cohorts of the phase 1 study of MCG018. In the meantime, the biotech stock is likely to remain highly volatile.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

MacroGenics Stock Quote
$6.90 (-0.29%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.